---
title: "Atea Pharmaceuticals (AVIR.US) — Financial Reports"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/AVIR.US/norm.md"
symbol: "AVIR.US"
name: "Atea Pharmaceuticals"
parent: "https://longbridge.com/en/quote/AVIR.US.md"
datetime: "2026-05-21T15:55:56.355Z"
locales:
  - [en](https://longbridge.com/en/quote/AVIR.US/norm.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AVIR.US/norm.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AVIR.US/norm.md)
---

# Atea Pharmaceuticals (AVIR.US) — Financial Reports

## Income Statement (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| EPS | -0.5738 | -0.5743 | -0.5319 | -0.4437 | -0.4024 |
| ROE | -71.40% | -60.71% | -49.45% | -38.33% | -32.26% |
| Revenue | - | - | - | - | - |
| Net income | -45.44M | -44.87M | -42.05M | -37.16M | -34.27M |
| Operating income | -48.01M | -54.71M | -45.45M | -41.42M | -37.81M |
| Gross margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| Profit quality | - | - | - | - | - |

## Balance Sheet (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| A&L | 267.08M | 315.22M | 342.96M | 391.61M | 439.96M |
| Leverage | 1.14 | 1.14 | 1.09 | 1.07 | 1.07 |
| BVPS | 2.92 | 3.53 | 4.04 | 4.49 | 4.80 |
| Turnover | - | - | - | - | - |
| Cash & STI | 256.01M | 301.83M | 329.31M | 379.71M | 425.44M |
| Inv & Rec | - | - | - | - | - |
| LT assets | 831000.00 | 1.09M | 1.35M | 1.61M | 1.86M |
| Net debt | -255.37M | -300.99M | -328.26M | -378.47M | -423.99M |

## Cash Flow Statement (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| Operating CF | -46.39M | -28.22M | -40.38M | -32.87M | -30.56M |
| Investing CF | 29.74M | 46.59M | 41.30M | 15.29M | 85.61M |
| Financing CF | 257000.00 | 0.0000 | -11.30M | -14.09M | -347000.00 |
| Free CF | -30.41M | -12.24M | -24.68M | -20.38M | -14.08M |
| OCF coverage | - | - | - | - | - |
| Repaid & issued | - | - | - | - | - |
| CapEx | - | - | - | - | - |